This is an interesting article - not just about breast cancer treatment - but raises the questions about repurposement of drugs. One presumes that the evidence described within the article is solid because it was published in Lancet - but no description of the data (evidence) is described.

It also scores badly for balance - because it is unclear if the pharma companies that are reported to be resistant to studying the drug have been contacted for comment - or why they may not want to make money from a drug already on the market - if it is going to be such a game changer.

Clarity also scores relatively poorly because the Lancet authors own words are cited but often slightly clumsily making this tabloid read a bit trickier than one might expect of a broadsheet.

Kudos should be offered however for some cross referencing to broaden readers understanding of global breast cancer risk by linking the op-ed to the WHO_int and NHS websites.